NYVAC has been engineered as a safe, attenuated vaccinia virus (VV) vector for use in vaccination against a broad spectrum of pathogens and
tumors. Due to the interest in NYVAC-based vectors as
vaccines and current phase I/II clinical trials with this vector, there is a need to analyze the human host response to NYVAC
infection. Using high-density
cDNA microarrays, we found 368 differentially regulated genes after NYVAC
infection of HeLa cells. Clustering of the regulated genes identified six discrete gene clusters with altered expression patterns. Clusters 1 to 3 represented 47.5% of the regulated genes, with three patterns of gene activation kinetics, whereas clusters 4 to 6 showed distinct repression kinetics. Quantitative real-time reverse transcription-PCR analysis of selected genes validated the array data. Upregulated transcripts correlated with genes implicated in immune responses, including those encoding
interleukin-1 receptor 2 (IL-1R2),
IL-6, ISG-15, CD-80, and TNFSF7. NYVAC upregulated several intermediates of apoptotic cascades, including
caspase-9, correlating with its ability to induce apoptosis. NYVAC
infection also stimulated the expression of NF-kappaB1 and
NF-kappaB2 as well as that of
NF-kappaB target genes. Expression of the VV host range K1L gene during NYVAC
infection prevented
NF-kappaB activation, but not the induction of apoptosis. This study is the first overall analysis of the transcriptional response of human cells to NYVAC
infection and provides a framework for future functional studies to evaluate this vector and its derivatives as human
vaccines.